COVERMOX 400

Moxifloxacin is a fourth-generation fluoroquinolone antibiotic that represents the pinnacle of quinolone pharmacological development. Like all fluoroquinolones, it inhibits DNA gyrase and topoisomerase IV, but its C-7 and C-8 methoxy group modifications provide three qualitative advantages over second and third-generation agents: superior gram-positive activity, enhanced anaerobic coverage, and more potent atypical organism activity.

Moxifloxacin's selectivity for bacterial topoisomerase IV over DNA gyrase in gram-positive organisms is significantly higher than ciprofloxacin or levofloxacin — translating to superior S. pneumoniae activity (including levofloxacin-resistant pneumococci), Staphylococci (MSSA), and Streptococci. This gram-positive potency, combined with the broad gram-negative and atypical coverage shared across the fluoroquinolone class, gives moxifloxacin the broadest single-agent antibacterial spectrum of any oral antibiotic.

Uniquely among fluoroquinolones, moxifloxacin covers anaerobic bacteria — Bacteroides fragilis, Peptostreptococcus, Clostridium species — a spectrum extension that makes it valuable for intra-abdominal infections and polymicrobial infections where standard fluoroquinolones have no anaerobic activity. The C-8 methoxy group responsible for anaerobic coverage also reduces the risk of photosensitivity compared to older fluoroquinolones.

At 400mg once daily, moxifloxacin achieves plasma concentrations with an AUC/MIC ratio that virtually eliminates resistance selection for susceptible organisms. Its oral bioavailability of ~90% produces near-IV drug exposure, enabling outpatient management of infections that would otherwise require hospitalisation.

COVERMOX 400 is a reserve-class antibiotic for moderate-to-severe infections where the broadest-spectrum oral monotherapy is clinically required, or where other fluoroquinolones have failed or are contraindicated.

Community-Acquired Pneumonia (Primary Indication): Moxifloxacin is IDSA/ATS guideline-recommended as monotherapy for outpatient CAP — covering S. pneumoniae (including drug-resistant strains), H. influenzae, M. catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in a single once-daily tablet. It is the preferred fluoroquinolone for CAP specifically because of its superior pneumococcal activity.

Acute Bacterial Sinusitis (Severe): For sinusitis unresponsive to standard antibiotic courses, moxifloxacin provides broad coverage of resistant S. pneumoniae, H. influenzae, and anaerobic organisms in sinus infections.

Intra-Abdominal Infections: Mild-to-moderate intra-abdominal infections where moxifloxacin's unique anaerobic coverage makes it one of the few fluoroquinolones suitable without adding a nitroimidazole.

MDR-TB: Moxifloxacin is a WHO Group A agent in MDR-TB treatment regimens — one of the most important fluoroquinolones for drug-resistant tuberculosis management.

Complicated Skin Infections: Mixed infections with gram-positive, gram-negative, and anaerobic organisms where moxifloxacin's broad spectrum enables single-agent oral management.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.